Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.056 NOK | +2.52% | -2.22% | -18.14% |
28/02 | Transcript : Thor Medical ASA, H2 2023 Earnings Call, Feb 28, 2024 | |
14/02 | Thor Medical ASA Announces CEO Changes | CI |
Valuation
Fiscal Period: December | 2023 |
---|---|
Capitalization 1 | 301.3 |
Enterprise Value (EV) 1 | 259.5 |
P/E ratio | -8.49 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | -3,79,99,461 x |
EV / FCF | -74,33,565 x |
FCF Yield | -0% |
Price to Book | 1.11 x |
Nbr of stocks (in thousands) | 2,33,539 |
Reference price 2 | 1.290 |
Announcement Date | 21/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net sales | - | - |
EBITDA | - | -6.829 |
EBIT | - | -7.16 |
Operating Margin | - | - |
Earnings before Tax (EBT) | - | -5.561 |
Net income 1 | -311.2 | -26.56 |
Net margin | - | - |
EPS 2 | -2.703 | -0.1520 |
Free Cash Flow | - | -34.91 |
FCF margin | - | - |
FCF Conversion (EBITDA) | - | - |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 21/03/24 | 21/03/24 |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net Debt 1 | - | - |
Net Cash position 1 | 98.6 | 41.8 |
Leverage (Debt/EBITDA) | - | - |
Free Cash Flow | - | -34.9 |
ROE (net income / shareholders' equity) | - | -3.31% |
ROA (Net income/ Total Assets) | - | -2.03% |
Assets 1 | - | 1,307 |
Book Value Per Share 2 | 0.5500 | 1.160 |
Cash Flow per Share 2 | 0.8600 | 0.1800 |
Capex 1 | 5.63 | - |
Capex / Sales | - | - |
Announcement Date | 21/03/24 | 21/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-18.14% | 21.9M | |
-1.43% | 103B | |
+8.96% | 101B | |
+4.40% | 23.07B | |
-12.15% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.04% | 16.94B | |
+6.79% | 14.07B | |
+38.61% | 12.35B |
- Stock Market
- Equities
- NANOV Stock
- Financials Thor Medical